Jamjoom Pharmaceuticals Factory (Jamjoom Pharma) has entered into an exclusive agreement with Idorsia for the distribution and commercialization of QUVIVIQ (daridorexant) in Saudi Arabia and the Levant region.
The agreement gives Jamjoom Pharma the marketing authorization and full commercial responsibility for QUVIVIQ, Idorsia’s first-in-class dual orexin receptor antagonist for adults with insomnia, across Saudi Arabia and the Levant, adding a differentiated, science-backed sleep therapy to a portfolio already recognized for its depth in ophthalmology, dermatology, and chronic disease care.
Tarek Hosni, Chief Executive Officer of Jamjoom Pharma, commented that, “Insomnia affects millions of people across our region, yet it remains widely under-diagnosed and under-treated. Bringing QUVIVIQ to Saudi Arabia and the Levant is a direct extension of what we set out to do more than two decades ago: put safe, effective, and modern therapies within reach of the patients who need them most.”
“This partnership builds on the strength of our regulatory expertise, our manufacturing and distribution network across more than 37 countries, and our belief that every community we serve deserves access to world-class healthcare. It is another step in our journey to become the leading healthcare organization in the Middle East and Africa by 2030, in line with Saudi Vision 2030,” Hosni added.
Benjamin Limal, President of Europe & International Markets for Idorsia, noted that, “With Jamjoom’s strong market presence, deep regulatory expertise, and well-established commercial infrastructure, Jamjoom Pharma is ideally positioned to support the successful launch and broad access of our innovative insomnia treatment. As we continue to execute our international growth strategy for QUVIVIQ, partnerships such as this are instrumental in expanding commercialization across new geographies and maximizing patient access globally.”
Under the terms of the agreement, Jamjoom Pharma will hold the marketing authorization for QUVIVIQ in Saudi Arabia. It will lead all regulatory, distribution, promotion, and commercialization activities across Saudi Arabia and the Levant region, drawing on its established commercial infrastructure and regional market knowledge.
Idorsia will supply the finished drug product for the agreed territories and will receive an upfront payment along with additional payments, including royalties on net sales.
The QUVIVIQ agreement is the latest milestone in a broader expansion strategy that has seen Jamjoom Pharma grow into a diversified healthcare partner present across the Middle East and Africa region.
Adding QUVIVIQ to its therapeutic offering allows Jamjoom Pharma to extend its patient-centered approach in central nervous system care, complementing its established strength in the CNS space as well as diversified chronic disease management. For a region where poor sleep quality is known to affect concentration, mood, and long-term health, the company sees the introduction of a modern, non-sedative treatment option as a meaningful contribution to public health, as per the statement.
